161 related articles for article (PubMed ID: 29748599)
1. Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan.
Chang YS; Lee WJ; Lim CC; Wang SH; Hsu SM; Chen YC; Cheng CY; Teng YT; Huang YH; Lai CC; Tseng SH
Sci Rep; 2018 May; 8(1):7486. PubMed ID: 29748599
[TBL] [Abstract][Full Text] [Related]
2. The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes.
Zarranz-Ventura J; Liew G; Johnston RL; Xing W; Akerele T; McKibbin M; Downey L; Natha S; Chakravarthy U; Bailey C; Khan R; Antcliff R; Armstrong S; Varma A; Kumar V; Tsaloumas M; Mandal K; Bunce C; Tufail A;
Ophthalmology; 2014 Oct; 121(10):1966-75. PubMed ID: 24953791
[TBL] [Abstract][Full Text] [Related]
3. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
Rahimy E; Rayess N; Ho AC; Regillo CD
Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
[TBL] [Abstract][Full Text] [Related]
4. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
Shin JY; Kwon KY; Byeon SH
Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
[TBL] [Abstract][Full Text] [Related]
5. Choroidal Thickness Changes After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration.
Minnella AM; Federici M; Falsini B; Barbano L; Gambini G; Lanza A; Caporossi A; Savastano MC
BioDrugs; 2016 Aug; 30(4):353-9. PubMed ID: 27189458
[TBL] [Abstract][Full Text] [Related]
6. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept.
Kaya F
J Fr Ophtalmol; 2017 Dec; 40(10):832-838. PubMed ID: 29113742
[TBL] [Abstract][Full Text] [Related]
7. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
[TBL] [Abstract][Full Text] [Related]
8. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes.
Butt T; Lee A; Lee C; Tufail A;
BMJ Open; 2015 May; 5(5):e006535. PubMed ID: 25943370
[TBL] [Abstract][Full Text] [Related]
10. RANIBIZUMAB AND AFLIBERCEPT FOR THE TREATMENT OF PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Data from an Observational Study.
Vaze A; Nguyen V; Daien V; Arnold JJ; Young SH; Cheung CM; Lamoureux E; Bhargava M; Barthelmes D; Gillies MC;
Retina; 2018 Oct; 38(10):1954-1961. PubMed ID: 28820848
[TBL] [Abstract][Full Text] [Related]
11. A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study.
Wu WC; Chen JT; Tsai CY; Wu CL; Cheng CK; Shen YD; Tsai A; Wu PC
BMC Ophthalmol; 2020 Nov; 20(1):462. PubMed ID: 33238968
[TBL] [Abstract][Full Text] [Related]
12. Choroidal thickness and visual prognosis in type 1 lesion due to neovascular age-related macular degeneration.
Hernández-Martínez P; Dolz-Marco R; Hervás-Marín D; Andreu-Fenoll M; Gallego-Pinazo R; Arévalo JF
Eur J Ophthalmol; 2017 Mar; 27(2):196-200. PubMed ID: 27646337
[TBL] [Abstract][Full Text] [Related]
13. Ranibizumab reimbursement and treatment patterns for neovascular age-related macular degeneration in Taiwan - Results from the 12-month, observational RENOWNED study.
Chen SN; Lai CC; Wang JK; Choi HY; Kuo CN; Tsai CY; Wang HI; Yang CM
J Formos Med Assoc; 2022 Oct; 121(10):2020-2027. PubMed ID: 35279311
[TBL] [Abstract][Full Text] [Related]
14. The role of indocyanine green angiography imaging in further differential diagnosis of patients with nAMD who are morphologically poor responders to ranibizumab in a real-life setting.
Ozkaya A; Alagoz C; Garip R; Alkin Z; Perente I; Yazici AT; Taskapili M
Eye (Lond); 2016 Jul; 30(7):958-65. PubMed ID: 27080484
[TBL] [Abstract][Full Text] [Related]
15. RETICULAR PSEUDODRUSEN ARE NOT A PREDICTIVE FACTOR FOR THE 1-YEAR RESPONSE TO INTRAVITREAL RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Nghiem-Buffet S; Giocanti-Auregan A; Jung C; Dubois L; Dourmad P; Galbadon L; Fajnkuchen F; Quentel G; Cohen SY
Retina; 2017 Jan; 37(1):53-59. PubMed ID: 27380430
[TBL] [Abstract][Full Text] [Related]
16. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
[TBL] [Abstract][Full Text] [Related]
17. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab.
Stangos AN; Gandhi JS; Nair-Sahni J; Heimann H; Pournaras CJ; Harding SP
Am J Ophthalmol; 2010 Nov; 150(5):666-73. PubMed ID: 20719300
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review.
Bandukwala T; Muni RH; Schwartz C; Eng KT; Kertes PJ
Can J Ophthalmol; 2010 Dec; 45(6):590-5. PubMed ID: 21135894
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration.
Roller AB; Amaro MH
Arq Bras Oftalmol; 2009; 72(5):677-81. PubMed ID: 20027409
[TBL] [Abstract][Full Text] [Related]
20. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
Lee H; Ji B; Chung H; Kim HC
Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
